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Disorders of sex development (DSD) consist of a wide range of conditions involving 
numerous genes. Nevertheless, about half of 46,XY individuals remain genetically 
unsolved. GATA4 gene variants, mainly related to congenital heart defects (CHD), have 
also been recently associated with 46,XY DSD. In this study, we characterized three 
individuals presenting with 46,XY DSD with or without CHD and GATA4 variants in order 
to understand the phenotypical variability. We studied one patient presenting CHD and 
46,XY gonadal dysgenesis, and two patients with a history of genetically unsolved 46,XY 
DSD, also known as male primary hypogonadism. Mutation analysis was carried out 
by candidate gene approach or targeted gene panel sequencing. Functional activity of 
GATA4 variants was tested in vitro on the CYP17 promoter involved in sex development 
using JEG3 cells. We found two novel and one previously described GATA4 variants 
located in the N-terminal zinc finger domain of the protein. Cys238Arg variant lost tran-
scriptional activity on the CYP17 promoter reporter, while Trp228Cys and Pro226Leu 
behaved similar to wild type. These results were in line with bioinformatics simulation 
studies. Additional DSD variations, in the LRP4 and LHCGR genes, respectively, were 
identified in the two 46,XY individuals without CHD. Overall, our study shows that human 
GATA4 mutations identified in patients with 46,XY DSD may or may not be associated 
with CHD. Possible explanations for phenotypical variability may comprise incomplete 
penetrance, variable sensitivity of partner genes, and oligogenic mechanisms.
Keywords: disorder of sexual development, DsD, gaTa4, congenital heart defects, oligogenic, 46,XY DsD
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inTrODUcTiOn
Disorders of sex development (DSD) are defined as congenital 
conditions, in which development of chromosomal, gonadal, or 
anatomical sex is atypical (1). 46,XY DSD includes disorders in 
male gonad determination and differentiation, androgen biosyn-
thesis or action, and anti-Müllerian hormone (AMH) synthesis 
or action (1). In the last two decades, numerous genes have been 
found to cause 46,XY DSD (2). In about 40% of 46,XY DSD 
individuals, the underlying genetic cause still remains unsolved. 
GATA4 has been more recently implicated in 46,XY DSD.
The GATA family of transcription factors consists of six mem-
bers, three expressed in hematopoietic stem cells (GATA1–3) and 
three in tissues derived from mesoderm and endoderm, includ-
ing heart, gonad, lung, liver, and gut (GATA4–6). GATA factors 
regulate tissue-specific gene expression either alone or in coop-
eration with other factors (3, 4). GATA proteins have two zinc 
fingers (ZNI and ZNII), which are highly conserved while the 
sequences of the amino-terminal and carboxyl-terminal domains 
exhibit lower similarities (5, 6). While the C-terminal zinc finger 
region is required for the DNA recognition and binding, and the 
N-terminal zinc finger region contributes to the stability, both 
zinc fingers are necessary for protein–protein interactions with 
other transcription factors (4, 7).
The human GATA4 gene on chromosome 8p23.1 encodes an 
essential transcription factor for the developing gonad (8) and 
heart (9, 10). Gata4-null mice die due to severe abnormalities in 
heart tube formation and ventral morphogenesis (9, 10). Gata4 
expression and function seems required for normal testicular 
and genital development (11–14). Human GATA4 interacts with 
several proteins, including NR5A1, WT1, and FOG2 to regulate 
the expression of sex determining genes SRY, SOX9, and AMH, 
as well as genes involved in sex differentiation such as StAR, 
CYP17A1, CYP19A1, INHA, and HSD3B2 (15–18).
In humans, GATA4 haploinsufficiency has been described in 
patients with different forms of congenital heart defects (CHD) 
since 1999 (OMIM_600576). So far more than 120 GATA4 gene 
variants have been associated with cardiac defects (HGMD® pro-
fessional 2017, accessed October 2017), while only four studies 
reported mutations related to a 46,XY DSD phenotype (19–22).
Overall, GATA4 gene variations seem more likely to result 
in CHD than DSD, but the reason for this is unclear. And the 
fact that some individuals with GATA4 haploinsufficiency have a 
46,XY DSD phenotype only remains similarly unexplained.
We, therefore, characterized three additional individuals 
presenting with 46,XY DSD and two novel and one previously 
described GATA4 variants. They presented with or without CHD, 
but additional variants in two other genes were found that likely 
contributed to the DSD phenotype.
MaTerials anD MeThODs
ethical approval
Written informed consent was obtained from all subjects and 
their family members at the respective hospitals involved. The 
study was approved by the local ethical committees, namely the 
ethical boards of the La Fe University Hospital, Valencia, Spain, 
the St. Anna Children’s Hospital, Vienna, Austria, as well as the 
ethics committee for clinical research of Euskadi (CEIC-E), Spain.
genetic analysis
Genomic DNA was isolated from peripheral blood leukocytes 
and analyzed for genetic alterations causing DSD using different 
approaches.
Case 1 was first studied by a candidate gene approach. GATA4 
gene segments corresponding to the 5′UTR region, the 6 cod-
ing exons and their flanking intronic sequences were amplified 
by PCR using specific primers [Table S1 in Supplementary 
Material; (21)]. The PCR products were sequenced using the 
BigDye Terminator v3.1 Cycle Sequencing Kit on an automated 
ABI PRISM 3100 Genetic Analyzer (Applied biosystems, 
Foster City, CA, USA). Obtained sequences were analyzed and 
compared with the wild-type (wt) published reference sequence 
(RefSeq NM_002052) using SeqScape Software v. 2.5 (Applied 
Biosystems). The DNA sample was in addition studied on a 
sequencing panel (TruSight One Sequencing Panel, Illumina, 
San Diego, CA, USA) containing 4,813 disease-associated 
genes, including 94 well-known candidate genes for DSD 46,XY 
and 46,XX.
Case 2 was examined on the target gene panel for DSD by 
Haloplex technology (Agilent, Santa Clara, CA, USA). This 
system allowed to simultaneously sequence 64 diagnostic genes 
for DSD and 967 candidate genes (19).
Case 3 was analyzed by a customized Ion Ampliseq panel 
(ThermoFisher Scientific, Waltham, MA, USA) comprising cod-
ing and flanking regions of 48 DSD genes. Analysis was performed 
according to the manufacturer’s instructions.
Of note, GATA4 variants identified by panel analysis were 
verified by Sanger sequencing. Parents and affected family mem-
bers were tested to establish the mode of inheritance.
Identified GATA4 sequence variants were then evaluated for 
their possible functional significance in  silico using prediction 
software programs, including SIFT,1 Provean,2 PolyPhen-2,3 
MutationTaster,4 MutPred,5 and SNPs&GO.6
In all three cases, the involved clinician informed the patient 
about the genetic results, including information on pathogenic, 
probably pathogenic, and uncertain findings with regard to the 
DSD/genital phenotype. Incidental findings were not made.
In Vitro Functional studies
Human placental JEG3 cells (3002227), human adrenal NCI-
H295R cells (ATCC CRL-21288), and non-steroidogenic human 
embryonic kidney HEK293 cells (ATCC CRL-1573) were 
cultured as described (18, 23) and used for functional assays. 
1 http://sift.jcvi.org/ (Accessed: March, 2017).
2 http://provean.jcvi.org/index.php (Accessed: March, 2017).
3 http://genetics.bwh.harvard.edu/pph2/ (Accessed: March, 2017).
4 http://www.mutationtaster.org/ (Accessed: March, 2017).
5 http://mutpred.mutdb.org/ (Accessed: March, 2017).
6 https://snps-and-go.biocomp.unibo.it/snps-and-go/ (Accessed: March, 2017).
7 http://www.clsgmbh.de/ (Accessed: April, 2017).
8 http://www.lgcstandards-atcc.org (Accessed: April, 2017).
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Promoter luciferase reporter vector −227CYP17A1_Δluc was 
available from previous work (18). Promoter reporter vectors 
pGL3AMH and pGL3SRY were cloned by PCR amplifying 
the fragments of −1,067/+32 SRY and −951/+115 AMH from 
human genomic wt DNA and inserting the fragments into pGL3 
basic (Promega, Dübendorf, Switzerland). Vectors were verified 
by direct sequencing.
Human wt GATA4 cDNA was inserted into the mammalian 
pCMV expression vector. GATA4 mutations c.684A, c.712C, 
and c.677T were generated by site-directed mutagenesis using 
specific primers and the QuickChange protocol by Stratagene 
(Agilent technologies Inc., Santa Clara, CA, USA). We also 
constructed the previously described c.661A GATA4 variant 
for comparison (21). Mutant plasmids were confirmed by direct 
sequencing.
For functional studies, cells were cultured on 12-well plates 
and transiently transfected with wt or mutant GATA4 vectors 
and a CYP17 promoter reporter using a calcium phosphate 
transfection protocol (Invitrogen, ThermoFisher Scientific). 
48  h after transfection, cells were washed and lysed, before 
luciferase activity was measured with the Dual-Luciferase® 
Reporter (DLR™) Assay system (Promega AG, Wallisellen, 
Switzerland) on a Veritas microplate Luminometer reader 
(Turner Bio systems Luminometer and Software by Promega). 
Specific Firefly luciferase readings were standardized against 
Renilla control readings and results expressed as relative 
luciferase units. Results are shown as the mean ± SEM of four 
independent experiments, all performed in duplicate. Data were 
statistically analyzed using the Student’s t test. A p-value ≤ 0.05 
was considered significant.
Protein structure analysis
Since the structure of GATA4 protein is not known, a hybrid 
homology model of the protein was made using YASARA (24) 
and AMBER. Three rounds of PSI-BLAST were performed 
with the GATA4 amino acid sequence (NP_002043) to build a 
position-specific scoring matrix, and then a search of protein 
structure database was conducted to find the templates for 
model generation. Structures of GATA3 (PDB # 4HC9 and 
4HC7) and GATA1 (PDB # 3VD6 and 3VEK) were found to 
be best templates for making the GATA4 protein model. Using 
each template separately several models were made. Three loops 
from amino acid sequences NLDMFDDFSE, KNLNKSKTPA, 
and LIKPQRRLSASRRVGL needed to be modeled separately 
and joined in the structure. Side chains of modeled amino acids 
were optimized by screening of rotamer libraries and molecular 
dynamics (MD) simulations. Best quality parts from different 
models were then combined to generate a hybrid model, which 
had increased coverage and accuracy compared to individual 
models. In silico mutagenesis was performed to create the GATA4 
mutations described in this report (25), which were then further 
refined by brief MD simulations of 500 ps. All models were then 
subjected 500 steps of steepest descent and simulated annealing 
minimizations using AMBER14 force filed and TIP3P water 
model (26, 27), and then subjected to 25  ns of explicit solvent 
MD simulations at 310 K. Structural analysis was performed after 
the MD simulation systems were stable. All illustrations were 
prepared with PyMOL9 and rendered as ray-traced images using 
PovRay.10
resUlTs
cases reports of Three 46,XY DsD 
Patients harboring gaTa4 gene Variations
Case 1
This “female” newborn was referred after birth because of ambigu-
ous genitalia (Table 1). She presented with a small vulva, slight 
clitoral hypertrophy, labia were fused in posterior raphe and gonads 
were palpable in inguinal canal. Karyotype was 46,XY. Ultrasound 
and pelvic MRI showed a rudimentary uterus. Biochemical and 
hormonal studies at presentation and during follow-up revealed 
more or less normal values (compared to male age-controls), only 
undetectable and low AMH was remarkable (Table 2). She was also 
seen by a pediatric cardiologist for a heart murmur and found to 
have a complex CHD, which was not detected in prenatal screen-
ing (Table 1). At 40 days of life, surgical closure of the ventricular 
septal defect was performed. It was then noted that she also had 
congenital compression of the left bronchus leading to an asym-
metry in the caliber of the pulmonary branches with a hypoplastic 
left branch. During follow-up over 3 years, she showed some signs 
of developmental delay. She is reared as a girl.
Case 2
Patient 2 presented micropenis with hypospadias and cryptor-
chidism at birth (Table 1). His karyotype was 46,XY. At 3 months 
of age, his gonadotropins were elevated at a testosterone of 
0.92  ng/ml (Table  2). At 7  months, spontaneous descensus 
of the left testis occurred, whereas the right testis was found 
inguinal. Stimulation test with hCG resulted in a normal rise of 
testosterone. He was treated for micropenis with testosterone 
(3 mg × 25 mg monthly), which increased phallic size from 2.0 
to 3.5 cm. At 17 months, right-sided orchidopexy was performed 
including biopsy. Histology revealed a sertoli-cell only phenotype; 
spermatogonia were not visible. Tubules appeared immature 
exhibiting a compressed, lumen-less structure. At follow-up at 
10 years of age, testicular sonography revealed multiple calcifica-
tions with a testis size of 0.5 ml on the right and 0.8 ml on the 
left. The boy was still prepubertal with a small phallus of 3 cm 
and a hypoplastic scrotum. Biochemically, luteinizing hormone 
(LH), follicle stimulating hormone (FSH), and testosterone were 
already on the rise. AMH and adrenal steroids were in the normal, 
age- and sex-appropriate range. Apart from the development of 
his external genitalia, the boy has been healthy and psychomotor 
development is normal. He has no CHD.
Family history is remarkable for the following: the boy’s mother 
is healthy with no fertility problems, but was diagnosed with a 
mitral valve prolapse in adulthood requiring no medical inter-
vention. According to cardiologists, mitral valve prolapse is often 
seen with aging and does not qualify as CHD. The maternal uncle 
9 www.pymol.org (Accessed: October, 2017).
10 www.povray.org (Accessed: October, 2017).
TaBle 2 | Biochemical characterization of three 46,XY DSD patients harboring variants in the GATA4 gene.
case adrenal function gonadal function
age at 
evaluation
acTh  
(pg/ml)
cortisol  
(μg/dl)
11-Deoxycortisol  
(ng/ml)
17OhP 
(ng/ml)
Dhea-s 
(ng/ml)
androstenedione  
(ng/ml)
T (ng/ml) Fsh  
(U/l)
lh  
(U/l)
estradiol 
(pg/ml)
aMh  
(ng/ml)
Basal Basal Basal Basal Basal Basal Basal after 
hcg
Basal Basal Basal Basal
1 2 days 243.0 11.3 11.4 4.4 1,660 1.30 0.2 0.1 59 <0.14
7 days 36.7 1.9
14 days 19.3 3.4 42
3.5 years 123 <0.3 <0.02 14.1 <0.1 <5.0 4.4
2 3 months 0.92 38 12.3
7 months 0.11 1.87
10 years 16 8.6 0.31 2.41 0.55 0.21 14.9 0.9 13 14.4
3 11 years 1.30 63.3 14
14 years 1.30 36.7 18.5
15 years 5.9a 1.5a <0.5a
21 years 11.8a 9.5a 4.0a
Laboratory test values outside the normal range of age and chromosomal sex are given in bold.
ACTH, adrenocorticotropic hormone; 17OHP, 17-hydroxyprogesterone; DHEA-S, dehydroepiandrosterone sulfate; T, testosterone; FSH, follicle stimulating hormone; LH, luteinizing 
hormone; AMH, anti-Müllerian hormone.
aUnder testosterone replacement treatment.
TaBle 1 | Clinical and genetic characterization of three 46,XY DSD patients harboring variants in the GATA4 gene.
case gender 
assigned
Phenotype genotype
genital anatomy at initial 
presentation
Müllerian 
ducts
gonadectomy chD syndromic features Karyotype GATA4 gene 
variant
Other DsD 
genes
1 F Clitoral hypertrophy, fused labia 
with posterior raphe, gonads 
palpable in inguinal canal
Rudimentary 
uterus
No. But, 
planned with 
cardiac surgery
Yes Developmental delay: 
sitting 12 months, 
crawling 18 months, 
walking 24 months; at 
3 years no language 
skills, signs of autism
46,XY c.712T>C; 
p.Cys238Arg
None
2 M Micropenis, hypospadias, bilateral 
cryptorchidism
No No No No 46,XY c.684G>C; 
p.Trp228Cys
LRP4 
(c.5660C>G; 
p.Ser1887Cys)
3 M Micropenis, bilateral 
cryptorchidism (inguinal)
No No No Severe obesity 46,XY c.677C>T; 
p.Pro226Leu
LHCGR 
(c.1660C>T; 
p.Arg554Stop)
All sequence information about GATA4 gene is based on NM_002052. LRP4 and LHCGR information is based on NM_002334 and NM_000233, respectively.
CHD, congenital heart defects; LHCGR, luteinizing hormone/choriogonadotropin receptor; LRP4, LDL receptor-related protein 4.
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had a similar history as the patient with micropenis and bilateral 
cryptorchidism at birth. Orchidopexy and testosterone treatment 
for micropenis were performed in early childhood. Pubertal 
onset occurred spontaneously and no testosterone treatment was 
required. At 18 years of age, he had markedly elevated gonado-
tropins (LH 25.8 IU/l; FSH 53.8 IU/l) in the presence of a low-
normal testosterone. Testicular volume was 3  ml. Azoospermia 
was ascertained at 23  years and subsequent testicular biopsy 
revealed sertoli-cell only syndrome. During the following years, 
testosterone levels decreased continuously and AMH became 
undetectable. He is otherwise healthy, without signs of a CHD.
Case 3
This patient was noted at birth to have micropenis and bilateral 
cryptorchidism, but no action was taken (Table 1). At 11 years of 
age he still presented micropenis (3.5 cm), testes were non-palpable 
and severe obesity (BMI 36.6, +6.4 SD) was observed. His gon-
adotropins were elevated with low testosterone. Karyotype was 
46,XY. MRI showed both testes in inguinal canal. At 14.3 years, 
replacement testosterone treatment was started with gradual 
increasing doses. After treatment, LH suppression and normali-
zation of FSH was observed. At 18 years, azoospermia was found. 
At recent follow-up at 21 years of age, he presented with severe 
obesity (BMI 44.9, +6.8 SD) and short stature (156.1 cm). Penis 
(8 cm) was buried in subcutaneous fat and left testis was in scro-
tum (0.5 ml). Biochemically, he presented normal gonadotropins 
with a testosterone of 11.8 ng/ml under treatment. Ultrasound 
showed an ovoid structure (17 mm × 16 mm) in right inguinal 
canal corresponding to atrophic testis. Currently, laparoscopy is 
planned to investigate the right testis and biopsy both to assess the 
malignancy risk. Echocardiography revealed no CHD.
FigUre 1 | Schemes of the structure of the GATA4 protein and localization of studied variations. (a). GATA4 contains two distinct zinc finger domains (ZNI and ZNII) 
and a C-terminal nuclear localization sequence (NLS), which consists of a DNA-binding domain and a protein–protein interaction domain. Transcriptional activation 
domains (TAD) are located in the N-terminus. (B). Close-up loop of the ZNI domain of the C-terminus, where all GATA4 variations described so far in patients with a 
46,XY phenotype are located: Gly221Arg, Pro226Leu, Trp228Cys, and Cys238Arg.
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genetic characterization of Three novel 
GATA4 gene Variants
We found novel GATA4 gene variants in three patients presenting 
with 46,XY DSD at birth.
In case 1, direct analysis by Sanger sequencing revealed a 
T to C change in heterozygosis at position 712 (c.712T>C; 
p.Cys238Arg) in exon 3 of GATA4. Both parents were studied 
and did not carry the variant, thus this GATA4 variant is a de novo 
change in the patient.
In case 2, DSD targeted gene panel sequencing identified a 
heterozygous GATA4 c.684G>C nucleotide change, which is 
predicted to result in a p.Trp228Cys alteration. This variant has 
been previously listed in a publication by Eggers et al. reporting 
on DSD panel diagnostics (19). Remarkably, the patients’ mother 
presenting with a mitral valve prolapse, and his maternal uncle 
having a similar history of micropenis and cryptorchidism, were 
both carriers of the same heterozygous GATA4 variant.
In case 3, a heterozygous C to T transition located at c.677 of 
the coding GATA4 DNA sequence predicted to replace a proline 
with leucine at position p.226 (c.677C>T; p.Pro226Leu) was 
found by DSD targeted panel sequencing. The same heterozygous 
variant was also found in the healthy mother.
Looking at these GATA4 variants, it is remarkable that all 
are located in the N-terminal zinc finger domain of the GATA4 
protein (Figure  1), where the previously described variant 
p.Gly221Arg (found in a patient with 46,XY DSD) is also located 
(21). Prediction software programs and comparison of GATA4 
proteins across species revealed that Cys238, Trp228, and Pro226, 
and the surrounding region are highly conserved (Figure  2). 
Therefore, the identified GATA4 gene variants were predicted as 
potentially pathogenic.
additional (DsD) gene Variations identified 
by next generation sequencing (ngs)
In case 1, additional targeted exome sequencing of 4,813 disease-
causing genes, containing 94 genes related to DSD, did not reveal 
any further sequence variant. In cases 2 and 3, without CHD, 
DSD targeted gene sequencing identified two additional gene 
variations. Case 2 revealed a novel, heterozygous C to G change at 
position 5660 (c.5560C>G; p.Ser1887Cys) of the LDL receptor-
related protein 4 (LRP4) gene (OMIM 604270). This gene variant 
was also found in the mother and the maternal uncle. In case 3, 
a heterozygous change of cytosine to thymine was found at loca-
tion 1660 of the LHCGR gene (OMIM 152790). This mutation 
changes codon 554 from arginine to a stop codon (c.1160C>T; 
p.Arg554Stop) and has been previously reported (28). The mother 
did not carry this luteinizing hormone/choriogonadotropin 
receptor (LHCGR) mutation.
In Vitro Functional studies of novel gaTa4 
Variants
To test the transcriptional activity of identified GATA4 variants, 
we constructed mammalian expression vectors of wt and mutant 
GATA4 and tested them on three different promoters that have 
been described being regulated by GATA4, namely the AMH, 
SRY, and CYP17 promoters. For these studies, we used different 
FigUre 3 | Transcriptional activity of GATA4 variants on the CYP17A1 promoter. Human placental JEG3 cells were transfected with a CYP17-promoter luciferase 
reporter construct, and the activity of wild-type (wt) and mutant GATA4 to trans-activate the promoter was tested using the Promega Dual Luciferase readout 
system. Results are shown as the mean ± SEM of four independent experiments, all performed in duplicate. **p-Value ≤ 0.01.
FigUre 2 | Multiple alignment of parts of the GATA4 protein sequences across species. Localization of the newly identified human aa variants are given in red and 
seem highly conserved across species. The localization of the so far only GATA4 mutation reported to cause a 46,XY DSD phenotype (p.Gly221Arg) is given in bold 
and its localization is also highly conserved.
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cell systems (HEK293, NCI-H295R, and JEG3), but found that 
only JEG3 cells transfected with the CYP17 promoter revealed 
consistent results for comparing wt to mutant GATA4. We found 
that GATA4 variant Cys238Arg lost transcriptional activity 
(Figure 3) similar to the previously described Gly221Arg mutant 
(21). By contrast, GATA4 variants Trp228Cys and Pro226Leu 
activated the CYP17 promoter similar to wt.
In Silico gaTa4 Protein structure-Function 
analysis
Using the structures of GATA1 and GATA3 available in the pro-
tein structure database, we created a protein structure model of 
GATA4. GATA4 was modeled with dual zinc atoms, which were 
coordinated with cysteines (Figure  4). One Zn atom is bound 
to cysteines 217, 220, 238, and 241, while the second Zn atom is 
bound to cysteines 272, 275, 293, and 296. Mutation of any of these 
cysteine molecules as well as neighboring residues is expected 
to result in loss of Zn binding. Among the mutations studied in 
this report, we found the mutations Gly221Arg and Cys238Arg 
to cause loss of Zn binding leading to an unstable protein with 
predicted loss of function (Figure 4). The mutations Pro226Leu 
and Trp228Cys are involved in interaction with DNA and their 
effects were predicted to be variable. Since the core structure of 
the GATA4 protein is not expected to be affected by these two 
mutations, it is the interactions with different DNA fragments 
that is predicted to be changed. As we have observed in case of 
SF1 mutations, the mutations causing a change in the interaction 
with DNA can have variable effects (23). While interaction and 
activation of one partner sequence can be affected and may cause 
full or partial loss of activation, the newly created nucleotide 
recognition element due to mutations could interact and activate 
another promoter sequence, resulting in altered gene expression. 
In case of Gly221Arg, loss of interaction with FOG2 protein has 
been reported. Structural analysis of this mutation shows a likeli-
hood of unstable protein due to loss of Zn binding and therefore, 
an alteration in the interaction with GATA4 binding partners is 
expected.
DiscUssiOn
We characterized three human GATA4 sequence variations 
found in three individuals with a 46,XY DSD phenotype with and 
without CHD. These variants were all missense changes and were 
present in heterozygous form. NGS revealed additional likely 
FigUre 4 | GATA4 protein model and prediction of effects by mutations. The GATA4 protein model was made using the structures of GATA1 and GATA3 available 
in the protein structure database. After performing a structure-based search using Phi-BLAST, two different structures of GATA1 and GATA3 were selected and used 
for model building as described in Section “Materials and Methods.” (a) Structural of WT GATA4 showing the Zn coordination and binding to DNA. (B) The 
Gly221Arg mutation is predicted to cause disruption of Zn binding and protein instability, resulting in a loss of function mutation. (c) The mutation Pro226Leu is in 
the nucleotide interaction interface and was predicted to alter the recognition of promoter sequences for binding to GATA4. This can lead to variable effects with 
some promoters showing on effect while other could be affected. (D) The mutation Trp228Cys was also predicted to cause variable effects due to its proximity to 
DNA-binding interface of GATA4. Inclusion of extra cysteine was not predicted to cause the disruption of Zn binding as Cys228 in the mutant was far away from the 
Zn binding site. (e) The mutation Cys238Arg was predicted to cause loss of Zn binding, leading to an instable and non-functional GATA4 protein. (F) A close-up of 
the Cys238Arg mutation showing the loss of Zn coordination to cysteine due to introduction of the arginine, which could not bind the Zn molecule to stabilize the 
protein. A severe loss of function effect was predicted for the Cys238Arg mutation.
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disease causing variants in two other genes (so-called second 
hits), namely LRP4 or LHCGR, in two patients with a 46,XY DSD 
phenotype without CHD.
In both mice and men, GATA4 is expressed in the somatic 
cell population of the developing heart and gonads and plays 
an essential role in their development (8–10). Human GATA4 
mutations associated with cardiac malformations are described 
in numerous patients (Table S2 in Supplementary Material) and 
are located throughout the gene in the coding and non-coding 
sequence including 3′- and 5′-UTR (29–33). They comprise 
single nucleotide variants as well as deletions and duplications, 
which lead to missense/nonsense mutations or splicing errors 
and thus altered proteins or protein expression. Studies of the 
pathogenesis of CHD have reported that mutations in the GATA4 
gene decrease the ability to transactivate target genes or fail to 
interact with proteins involved in heart development (34, 35). 
Moreover, it has been recently demonstrated that common vari-
ants in a region of GATA4 3′UTR contribute to the risk of CHD 
by changing posttranscriptional gene regulation at the level of 
miRNA (36). Altogether, these studies show that GATA4 gene 
mutations contribute to the susceptibility of CHD. A list of these 
numerous GATA4 mutations discovered in patients with CHD 
so far is provided in Table S2 in Supplementary Material. For a 
more comprehensive review of the role of GATA4 in CHD we 
refer to Ref. (31).
By contrast, the few GATA4 missense mutations found in 
46,XY DSD individuals with or without CHD are all located in 
the N-terminal zinc finger domain, which is responsible for DNA 
binding and interaction with cofactors (4, 7).
Functional characterization of GATA4 variants with respect 
to the 46,XY DSD phenotype has only been performed for the 
p.Gly221Arg mutation so far (21). In vitro studies revealed that 
p.Gly221Arg lacked DNA binding, had impaired transactivation 
activity on the AMH promoter, and failed to bind cofactor FOG2. 
Functional testing of three GATA4 variants identified in 46,XY 
DSD individuals of our study showed similarly disruptive effect 
for the missense mutation p.Cys238Arg, but no effect on trans-
activation activity on the CYP17 promoter for GATA4 variants 
p.Pro226Leu and pTrp228Cys. While all these variants are con-
served across species (Figure  2) and located in the N-terminal 
zinc finger domain of GATA4 (Figure 1), only Gly221 and Cys238 
are close to Zn binding sites. The Gly221 is not directly involved 
in Zn binding but is situated next to Cys220 which binds the Zn 
atom, and therefore, the mutation Gly221Arg will disrupt the Zn 
binding, leading to a non-functional GATA4. The Cys238 binds Zn 
and its mutation to arginine leads to loss of Zn binding (Figure 4).
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GATA4 regulates the expression of multiple genes coding for 
hormones or components of the steroidogenic pathway during 
testis development and function. In Gata4ki mice with p.Val217Gly 
mutation interaction of Gata4 with cofactor Fog is abrogated, and 
consequently animals display anomalies of testis development 
(12–14). Moreover, GATA4 functionally interacts with NR5A1 in 
Sertoli cell cultures to positively regulate the expression of AMH, 
and therefore, it has been reported that mutations in NR5A1 may 
cause 46,XY DSD due to lack of interaction with GATA (15). No 
gonadal involvement is mostly detected in families with GATA4 
mutations and isolated CHD, possibly because some of the 
variants retain some DNA-binding activity and exhibit different 
degrees of transcriptional activation on gonadal promoters and 
thus, remain able to synergize with NR5A1. In the present study, 
the p.Cys238Arg mutation was found in a patient with a complex 
CHD, genital ambiguity, and persistent Müllerian ducts, which 
led to female gender assignment. We propose that cysteine to 
arginine change in position 238 of GATA4 lacks activity to bind 
DNA reducing the transactivation of AMH critically.
By contrast, variants p.Pro226Leu and pTrp228Cys found 
in cases 2 and 3 did not affect CYP17 promoter activity. These 
individuals had a less severe 46,XY DSD phenotype, were raised 
as males, and had no evidence of heart anomalies. White et al. 
(22) described a 35 kb deletion immediately 3′ UTR of the GATA4 
gene in a patient presenting with complete gonadal dysgenesis 
(GD). Additionally, Harrison et  al. (20) screened patients with 
46,XY DSD/GD with array CGH and found an infant presenting 
a deletion of 0.22 Mb upstream GATA4 in chromosome 8p23.1. 
Same deletion was found in his healthy mother and his maternal 
grandmother, who had CHD. The authors proposed that the 
identified rearrangements obviously do not affect the coding 
sequence of GATA4, and may, therefore, not manifest with CHD, 
but rather disrupt regulatory elements controlling gene expres-
sion essential in the developing gonad (22). Thus, the phenotypic 
variability could be explained by genetic modifiers (37, 38). In 
addition, GATA4 regulates multiple (gonadal) promoters to 
variable degrees, rendering some promoters more sensitive to 
haploinsufficiency than others (15–18, 21, 39). Structural changes 
caused by both the p.Pro226Leu and pTrp228Cys variations were 
not predicted to be disruptive and core GATA4 structure was not 
altered. Since the changes were in the DNA interaction sites, it 
is expected that both p.Pro226Leu and pTrp228Cys mutations 
could have altered binding and activation of some of GATA4 
interaction partners and could also bind to other promoters and 
potentially change the transcription of several other genes.
In fact, we found segregating genetic variants besides GATA4 
in cases 2 and 3 using NGS. In one 46,XY DSD subject without 
CHD, a heterozygote variant in LRP4 gene was found. Mutations 
in LRP4 have been related to the Cenani–Lenz syndactyly syn-
drome and disruption of canonical WNT/beta-catenin signaling 
(OMIM 604270), which is not only important in bone formation 
but also in sexual development (40).
In our other 46,XY DSD patient without CHD, a heterozygote 
mutation in LHCGR gene was found together with the GATA4 
variant. The same inactivating LHCGR mutation was previously 
reported in 46,XY DSD and 46,XX primary amenorrhea (28). 
LHCGR is essential for fetal differentiation of the neutral external 
genitalia into the male phenotype. Inactivating, homozygous, 
or compound heterozygous mutations of LHCGR cause resist-
ance to hormonal stimulation and varying degree of Leydig cell 
hypoplasia in 46,XY subjects (41–43). Looking at the 5′UTR of 
LHCGR, several GATA sites are present suggesting that GATA4 
may regulate this gene. Therefore, combined heterozygocity for 
GATA4 and LHCGR variants in our patient may explain the 
46,XY DSD phenotype.
Finally, phenotypical variability with same heterozygous 
GATA4 mutation (p.Gly221Arg) observed within same family 
manifesting with either 46,XY DSD or CHD only, indicates that 
there might be incomplete penetrance (21). Interestingly, the 
same observation was made in mice heterozygote for a Gata4 
deletion (44).
In conclusion, detailed characterization of three new 46,XY 
DSD patients with and without CHD harboring heterozygous 
GATA4 missense mutations in comparison to previously reported 
patients revealed possible explanations for phenotypical variability. 
Thereby incomplete penetrance, variable sensitivity, and oligogenic 
mechanisms may be considered. Interestingly, “double hits” com-
bining a GATA4 variant with LHCGR or LRP4 variants have been 
found in two individuals with a 46,XY DSD phenotype only.
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